Improvement of pharmacokinetics and antitumor activity against human hepatoma cell line by using adriamycin-entrapped stealth liposomes

Hiroyuki Shimizu, Koichiro Kumai, Ichiro Uyama, Sansei Shibata, Toshiaki Tagawa, Kazuhiro Nagaike, Tatsuji Yasuda, Masaki Kitajima, Takushi Tadakuma

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Preferential accumulation in the reticuloendothelial system is one of the major obstacles to the use of liposomes as a drug carrier for targeting therapy. To reduce their uptake, ganglioside GM1 was introduced into the components of conventional liposomes that had been used in our targeting experiments. Two types of such liposomes were prepared. Tissue distribution studies on Adriamycin entrapped in both types of liposomes clearly indicated that the uptake of Adriamycin by liver and spleen decreased to the level comparable to that of free Adriamycin administration. By contrast, the level of Adriamycin in the serum remains high, and some increase was observed in the accumulation to the tumor. Furthermore, Adriamycin in these liposomes, which were conjugated with anti-α-fetoprotein (AFP) antibody, inhibited the growth of AFP-positive human hepatoma Li-7 more efficiently than free Adriamycin or Adriamycin in antibody-conjugated conventional liposomes.

Original languageEnglish
Pages (from-to)186-193
Number of pages8
JournalJournal of Surgical Oncology
Volume62
Issue number3
DOIs
Publication statusPublished - 01-07-1996
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Improvement of pharmacokinetics and antitumor activity against human hepatoma cell line by using adriamycin-entrapped stealth liposomes'. Together they form a unique fingerprint.

Cite this